Cite
HARVARD Citation
Niesvizky, R. et al. (n.d.). Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Leukemia & lymphoma. 56 (12), pp. 3320-3328. [Online].